These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30539842)

  • 41. [Anti-tumor mechanism of norcantharidin for the implanted tumors of human gallbladder carcinoma in nude mice in vivo].
    Fan YZ; Zhao ZM; Fu JY; Chen CQ
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):618-22. PubMed ID: 16784656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model.
    Rui Y; Wang D; Hu D; Huang L
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S985-S992. PubMed ID: 30539834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo.
    Yang Y; Lv QJ; Du QY; Yang BH; Lin RX; Wang SQ
    World J Gastroenterol; 2005 Apr; 11(16):2491-6. PubMed ID: 15832424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Synthesis and anticancer activity of norcantharidin-galactose derivatives].
    Fan F; Sun XF
    Yao Xue Xue Bao; 2008 Feb; 43(2):157-61. PubMed ID: 18507342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
    Zhang S; Tang D; Zang W; Yin G; Dai J; Sun YU; Yang Z; Hoffman RM; Guo X
    Anticancer Res; 2017 Feb; 37(2):465-473. PubMed ID: 28179291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Studies on anti-hepatocarcinoma effect, pharmacokinetics and tissue distribution of carboxymethyl chitosan based norcantharidin conjugates.
    Chi J; Jiang Z; Chen X; Peng Y; Liu W; Han B; Han B
    Carbohydr Polym; 2019 Dec; 226():115297. PubMed ID: 31582090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment.
    Li M; Xu X; Lu F; Guo S
    Drug Deliv; 2014 Jun; 21(4):293-301. PubMed ID: 24156408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
    Shih WL; Yu FL; Chang CD; Liao MH; Wu HY; Lin PY
    Mol Carcinog; 2013 Oct; 52(10):800-12. PubMed ID: 22549898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preparation and pharmacological evaluation of norcantharidin-conjugated carboxymethyl chitosan in mice bearing hepatocellular carcinoma.
    Jiang Z; Chi J; Han B; Liu W
    Carbohydr Polym; 2017 Oct; 174():282-290. PubMed ID: 28821069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Norcantharidin enhances TIMP‑2 anti‑vasculogenic mimicry activity for human gallbladder cancers through downregulating MMP‑2 and MT1‑MMP.
    Zhu W; Sun W; Zhang JT; Liu ZY; Li XP; Fan YZ
    Int J Oncol; 2015 Feb; 46(2):627-40. PubMed ID: 25405519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells.
    Ding Z; Xu B; Zhang H; Wang Z; Sun L; Tang M; Ding M; Zhang T; Shi S
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Promising positive liver targeting delivery system based on arabinogalactan-anchored polymeric micelles of norcantharidin.
    Zhang Z; Yang L; Hou J; Xia X; Wang J; Ning Q; Jiang S
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S630-S640. PubMed ID: 30449176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis.
    Yan Z; Yang K; Tang X; Bi Y; Ding Y; Deng M; Xia D; Zhao Y; Chen T
    J Immunol Res; 2022; 2022():3851604. PubMed ID: 35497873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and anti-metastasis activities of norcantharidin-conjugated carboxymethyl chitosan as a novel drug delivery system.
    Chi J; Jiang Z; Qiao J; Peng Y; Liu W; Han B
    Carbohydr Polym; 2019 Jun; 214():80-89. PubMed ID: 30926011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma.
    Liu M; Tu J; Feng Y; Zhang J; Wu J
    J Nanobiotechnology; 2020 Aug; 18(1):114. PubMed ID: 32811502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of norcantharidin on the proliferation, apoptosis, and cell cycle of human mesangial cells.
    Ye K; Wei Q; Gong Z; Huang Y; Liu H; Li Y; Peng X
    Ren Fail; 2017 Nov; 39(1):458-464. PubMed ID: 28393592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.